Crimean-Congo hemorrhagic fever (CCHF)
Jump to navigation
Jump to search
Etiology
- Crimean-Congo hemorrhagic fever virus
Epidemiology
- first characterized in the Crimea in 1944
- later recognized in 1969 in the Congo
- Eastern & Souther Europe
- throughout the Mediterranean
- northwestern China
- central Asia
- Africa
- Middle East
- India
- tick-borne viral infection
Clinical manifestations
- sudden onset with headache, high fever, back pain, arthralgia, abdominal pain, & vomiting
- red eyes, facial flushing, pharyngitis, & petechiae on the palate are common
- jaundice may occu
- in severe cases, changes in mood & sensory perception
- severe bruising, severe epistaxis, & uncontrolled bleeding at injection sites beginning at day 4, lasting for 2 weeks[2]
Laboratory
- Crimean-Congo hemorrhagic fever virus IgG in serum
- Crimean-Congo hemorrhagic fever virus IgM in serum
- Crimean-Congo hemorrhagic fever virus RNA
Complications
- mortality in hospitalized patients 9-50%[2]
Management
More general terms
References
- ↑ Crimean-Congo haemorrhagic fever WHO Fact sheet N 208 January 2013 http://www.who.int/mediacentre/factsheets/fs208/en/
- ↑ 2.0 2.1 2.2 2.3 Centers for Disease Control & Prevention (CDC) Crimean-Congo Hemorrhagic Fever (CCHF) https://www.cdc.gov/vhf/crimean-congo/index.html
- ↑ Wikipedia: Crimean-Congo hemorrhagic fever https://en.wikipedia.org/wiki/Crimean%E2%80%93Congo_hemorrhagic_fever
- ↑ Appannanavar SB, Mishra B. An update on crimean congo hemorrhagic Fever. J Glob Infect Dis. 2011 Jul;3(3):285-92. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21887063 Free PMC Article
- ↑ Whitehouse CA Crimean-Congo hemorrhagic fever. Antiviral Res. 2004 Dec;64(3):145-60. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15550268